These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 26950292)

  • 21. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.
    Langer C; Soria JC
    Clin Lung Cancer; 2010 Mar; 11(2):82-90. PubMed ID: 20199973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments.
    Gridelli C; Maione P; Rossi A; De Marinis F
    Oncologist; 2007 Oct; 12(10):1183-93. PubMed ID: 17962612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Current progression of bevacizumab in advanced non-small cell lung cancer].
    Chu TQ; Chen JH; Han BH
    Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):793-800. PubMed ID: 30392346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiogenesis Inhibitors in NSCLC.
    Manzo A; Montanino A; Carillio G; Costanzo R; Sandomenico C; Normanno N; Piccirillo MC; Daniele G; Perrone F; Rocco G; Morabito A
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28934120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of anti-angiogenesis in non-small-cell lung cancer: an update.
    Villaruz LC; Socinski MA
    Curr Oncol Rep; 2015 Jun; 17(6):26. PubMed ID: 25947099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent developments of targeted therapies in the treatment of non-small cell lung cancer.
    Rossi A; Maione P; Colantuoni G; Ferrara C; Rossi E; Guerriero C; Nicolella D; Falanga M; Palazzolo G; Gridelli C
    Curr Drug Discov Technol; 2009 Jun; 6(2):91-102. PubMed ID: 19519336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC).
    Schmid-Bindert G
    Target Oncol; 2013 Mar; 8(1):15-26. PubMed ID: 23371029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted therapies in the treatment of advanced non-small-cell lung cancer: update.
    Mendoza L
    Klin Onkol; 2009; 22(4):131-8. PubMed ID: 19731875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
    Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Marsland T; Patel T; Rubin M; White L; Yang JC; Klughammer B; Colburn D; Miller V; Johnson BE
    J Thorac Oncol; 2014 Sep; 9(9):1411-7. PubMed ID: 25122437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety of second-line treatment options for non-small cell lung cancer.
    Rossi A; Maione P; Santabarbara G; Sacco PC; Casaluce F; Sgambato A; Barzelloni ML; Palazzolo G; Gridelli C
    Expert Opin Drug Saf; 2017 Apr; 16(4):471-479. PubMed ID: 28276858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unanswered questions: monoclonal antibodies in the treatment of advanced non-small-cell lung cancer.
    Gridelli C; Rossi A
    Oncology (Williston Park); 2010 Nov; 24(13):1216-23. PubMed ID: 21192561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
    Bonomi PD; Gandara D; Hirsch FR; Kerr KM; Obasaju C; Paz-Ares L; Bellomo C; Bradley JD; Bunn PA; Culligan M; Jett JR; Kim ES; Langer CJ; Natale RB; Novello S; Pérol M; Ramalingam SS; Reck M; Reynolds CH; Smit EF; Socinski MA; Spigel DR; Vansteenkiste JF; Wakelee H; Thatcher N
    Ann Oncol; 2018 Aug; 29(8):1701-1709. PubMed ID: 29905778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiogenesis inhibition in the treatment of lung cancer.
    Vokes E; Herbst R; Sandler A
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New antiangiogenetic agents and non-small cell lung cancer.
    Gridelli C; Rossi A; Maione P
    Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Necitumumab for non-small cell lung cancer.
    Greillier L; Tomasini P; Barlesi F
    Expert Opin Biol Ther; 2015; 15(8):1231-9. PubMed ID: 26051700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing chemotherapy and targeted agent combinations in NSCLC.
    Lynch T; Kim E
    Lung Cancer; 2005 Dec; 50 Suppl 2():S25-32. PubMed ID: 16557671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better….
    Di Maio M; Morabito A; Piccirillo MC; Daniele G; Giordano P; Costanzo R; Sandomenico C; Montanino A; Rocco G; Perrone F
    Curr Pharm Des; 2014; 20(24):3901-13. PubMed ID: 24191956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer.
    Reck M; Crinò L
    Lung Cancer; 2009 Jan; 63(1):1-9. PubMed ID: 18579254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.